Synaptic receptors of the nicotinic receptor gene family are pentamers of subunits. This modular structure creates problems in studies of drug actions, related to the number of copies of a subunit that are present and their position. A separate issue concerns the mechanism of action of many anesthetics, which involves potentiation of responses to neurotransmitters. Potentiation requires an interaction between a transmitter and a potentiator, mediated through the target receptor. We have studied the mechanism by which neurosteroids potentiate transmitter responses, using concatemers of covalently linked subunits to control the number and position of subunits in the assembled receptor and to selectively introduce mutations into positionally defined copies of a subunit. We found that the steroid needs to interact with only one site to produce potentiation, that the native sites for steroid interaction have indistinguishable properties, and that steroid potentiation appears to result from a global effect on receptor function.
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M
OST eukaryotic membrane channels are composed of several subunits assembled to make the functional channel, with the notable exceptions of the voltage-gated sodium and calcium channels that are translated as tandem repeats of four modules. The modular basis of the channels increases the diversity of possible functional properties, by allowing mixing and matching of various numbers and types of subunits. However, it also increases the difficulty in determining the molecular mechanisms for drug actions in two ways. First, it becomes necessary to control the number and position of particular subunits in the assembled channel. Otherwise, the concern is always present that a mixture of different subunit arrangements might result in a mixture of pharmacological effects. Second, if multiple copies of a subunit involved in a drug effect are present, it is difficult to distinguish the role or roles of the recognition or transduction regions in the positionally distinct copies. For many anesthetics, there is a third difficulty: they may act to potentiate responses to a transmitter. This mechanism requires that the transmitter and the anesthetic interact with each other through their separate interactions with the receptor. Does this mean that both must bind to the same subunit, or is the interaction mediated by a more global effect of the potentiator on the receptor?
How is it possible to create a receptor with defined subunits in defined places, given the problem that independent subunits assemble to create the final product? An experimental approach to controlling the number and position of subunits in a channel is to generate larger constructs that contain two or more subunits concatenated together. In a concatemer, the DNA coding for two or more separate subunits is covalently linked to result in the translation of a single, larger protein comprising the subunits in a defined linear order (see fig. 1 for schematic views of single subunits, the pentameric receptor, and concatemers). This approach was first used to generate dimers of voltage-gated potassium channel subunits. 1 Relatively soon after that it was extended to concatemers of ␥-aminobutyric acid type A (GABA A ) receptor subunits, 2 and now has been used in studies of other members of the voltage-gated channel family, [3] [4] [5] the nicotinic (or ligandgated) ion channel family, 6 -9 and some other channel types. 10, 11 We have been examining the ability of drugs to potentiate the agonist-elicited responses of receptors, with emphasis on the actions of neuroactive steroids. We will discuss the use of concatemers of subunits from two members of the ligand-gated ion channel family, a GABA A receptor, and a neuronal nicotinic receptor. Concatemers have allowed us to selectively manipulate steroid-or transmitter-binding sites and thereby determine the role or roles of particular sites and possible interactions among sites in a receptor.
Research Overview
A ligand-gated ion channel gene family receptor is composed of five subunits, arranged in a pseudosymmetric rosette around the centrally located ion channel ( fig. 1 ). There is an extensive N-terminal extracellular domain, which contains the binding sites for transmitters and several drugs. There are then three closely spaced transmembrane domains, followed by a variable length cytoplasmic loop. The subunit then finishes with a fourth transmembrane domain and a short extracellular C-terminal sequence ( fig. 1) . The major portion of the ion channel is formed by the second transmembrane domains from each of the five subunits. Channel gating is initiated by binding of transmitters to sites in the N-terminal extracellular domain and communicated to the gating region located in the transmembrane domains. Each of the subunits seems to be strongly coupled to the others in the receptor, in the sense that the process of channel opening appears to occur as a single, global step involving all subunits.
The agonist-binding site is located at an interface between two subunits, with each participating subunit contributing three loops. The assembled receptors we will discuss contain two agonist-binding sites per receptor. The conventional nomenclature is that the positive (primary or ϩ) subunit contributes the A, B, and C loops, while the negative (complementary or Ϫ) subunit contributes the D, E, and F loops ( fig. 1 ). For neuronal nicotinic receptors, the primary side is contributed by the ␣ subunit and the complementary side by the ␤ subunit. For the GABA A receptor, the primary side is contributed by the ␤ subunit and the complementary by the ␣. This discrepancy in nomenclature arose because subunits were initially named based on electrophoretic mobility.
We will discuss the actions of steroids to potentiate the responses of a prototypical GABA A receptor composed of ␣1, ␤2, and ␥2L subunits, and a neuronal nicotinic receptor composed of ␣4 and ␤2 subunits. These particular receptors are, respectively, the most common form of GABA A receptor and the most common heteromultimeric neuronal nicotinic receptor in the brain. (We note that some steroids and analogues can inhibit GABA A and/or nicotinic receptors. We will not consider this action.) Steroids and analogues are well known anesthetic drugs, [12] [13] [14] and indeed an anesthetic comprising a mixture of alphaxalone and alphadolone was used clinically (Althesin; Glaxo Laboratories Ltd., Greenford, England). A variety of studies have demonstrated that a number of neuroactive steroids potentiate the responses of GABA A receptors to low concentrations of the transmitter, ␥-aminobutyric acid (GABA). 13, 15, 16 Further, there is a good correlation between the ability of steroids and analogues to anesthetize amphibian tadpoles and their ability to modulate GABA A receptors, 16 supporting the idea that the anesthesia produced by these agents reflects actions at the GABA A receptor. The mechanism of action has been shown to result from an increase in the stability of the open-channel state of the receptor, rather than an increase in binding affinity or channel opening The blue-hatched segment is the signal sequence of the first subunit, the black segments are the "linkers" connecting subunits, and the subunits are schematized in red with membrane-spanning regions cross-hatched. The signal sequence is cleaved from the mature subunit and is not present in the assembled receptor. E shows a simplified version of a two-subunit concatemer in the membrane; other subunits are omitted for clarity. The cylinders outline the subunits, the red lines indicate the general course of the peptide in the subunit, and the black line indicates a hypothetical path for a linker to connect the subunits. rate. 17 Steroids are very hydrophobic molecules, and studies have indicated that the interaction between a steroid and a GABA A receptor occurs in the cell membrane. 18, 19 A major advance was made when a binding site for steroids was identified in the transmembrane regions of the ␣1 subunit, 20 and subsequently in other ␣ subunits. 21 It is possible to completely ablate steroid potentiation by mutations to a specific residue, ␣1 Q241, indicating the importance of this residue. 20, 22 There are two specific questions we have addressed using subunit concatemers. The first is concerned with the fact that the GABA A receptor includes two copies of the ␣1 subunit, each containing a steroid-binding site: Does a steroid need to bind to both sites to potentiate, and are the sites equivalent? The second is concerned with the fact that potentiation reflects binding of both steroid and agonist: Does the same subunit need to participate in both binding interactions, or is potentiation a distributed response of the entire receptor?
The nicotinic ␣4␤2 receptor is potentiated by the endogenous steroid, 17␤-estradiol (although most steroids and analogues inhibit this receptor, by a distinct mechanism 23, 24 ). The mechanism for potentiation is not known, but it seems likely that it reflects stabilization of the open state. 25 However, it is known that 17␤-estradiol interacts with a specific sequence of four amino acids at the extreme C-terminus of the ␣4 subunit. 24, 25 We asked similar questions in studies of this receptor: Does the C-terminal domain need to be on a specific subunit, does the subunit need to participate in agonist binding, and does the copy number of domains affect potentiation?
Concatemers
The basic portions of a concatemer are the two or more subunits that are joined together and the linker or linkers, or the new protein sequence that is introduced to connect the subunits.
How to make a concatemer? Our approach has been to use constructs first made by others with only minor modifications, so these comments reflect the insights gained in their work. It is very helpful that both ends (the amino-and carboxy-termini) of these subunits are on the same side of the membrane ( fig. 1 ), the extracellular side, which avoids problems of introducing (or removing) a membrane-spanning region. However, when initially translated each subunit has a "signal sequence" at the N-terminal end. The signal sequence assists in membrane insertion of the subunit during translation in the endoplasmic reticulum, and is subsequently cleaved so it is not present in the mature receptor. In the first concatemers, the signal sequence(s) were retained for all subunits in the concatemer, which resulted in a hybrid linker in which part was new protein and part was the existing signal sequence. 2, 7, 9 Most subsequent work has removed all the internal signal sequences, from all subunits except the first. 6, 8, 26 One comparison reported that removing internal signal sequences resulted in more normal pharmacological properties in pentameric concatemers. 26 The next question is what linker sequence should be used, and what secondary structure should it adopt? In general, the goal is to achieve a random coil, with the idea that this would place the least structural constraint on the concatemers as they assemble. The first linkers were simple repeats of glutamine residues.
2 Subsequently, linkers incorporating repeats of other amino acids have been used (e.g., alanineglycine-serine triplets). 8 The rationale for avoiding long repeats of identical amino acids is that such tracts might result in local depletion of transfer RNA molecules and possible early termination of synthesis.
Finally, how long should the linking sequence be? A linker that is too short reduces expression of functional receptors, as might be expected if a short linker caused structural deformations in the subunit that prevent correct assembly. 6, 8, 27 However, it appears that too long a linker can allow more variability in subunit arrangement in the pentamer. 8, 27 The best length seems to depend on the particular subunits being linked. Typically, the total length is estimated from the end of the fourth transmembrane region to the start of the following subunit mature sequence, and usually is in the range of 20 to 40 amino acid residues for wellbehaved constructs.
A number of concatemers of differing length were produced and used in various laboratories, dimers, 2,6 -8 trimers, 27, 28 and full pentamers of subunits. 26, 27, 29, 30 The full pentamer allows the most complete definition of subunit composition, but shorter concatemers have value in terms of ease of generation and manipulation, and can be preferred for some experiments. In our laboratories we have used dimers and trimers of subunits, as we will describe.
Two general types of studies have used concatemers. The first type has the objective of defining the properties of receptors with a defined number and arrangement of subunits. In this case, concatemers are produced that incorporate the subunits in particular orders. This approach has been particularly valuable in providing models for possible endogenous receptors whose stoichiometry is unknown. 27, 31, 32 For example, in the case of neuronal nicotinic receptors, it has provided the first evidence that receptors containing the ␣6 and ␤3 subunits can be studied in defined receptors. 27 It has also produced some surprising results indicating that so-called "accessory" subunits, or subunits that are not thought to contribute to transmitter-binding interfaces, may assemble in unpredicted ways. 31, 32 In the case of the GABA A receptor, the ␥ subunit is thought to assemble with 1 copy per receptor and to not contribute to a GABA-binding site. However, both the ␦ and subunits apparently can replace not only the ␥ subunit in the receptor, but also an ␣ or a ␤ subunit. 31, 32 The second type of experiment has the objective of defining the physiologic or pharmacological properties of specific subunits in a receptor, such as the roles of the two primary subunits in transmitter binding. 33 In this case, mutations are made in specific subunits in the concatemer to probe the similarities or differences in consequences for the overall re-ceptor function. Our work so far has focused on this second area. One previous report has been made using concatemers to study receptor modulation, of the interaction between the benzodiazepine-binding site and the GABA-binding sites in GABA A receptors. 34 In this study, benzodiazepine binding could potentiate responses elicited by GABA binding to either GABA-binding site.
The end result is that several laboratories have succeeded in expressing functional receptors using subunit concatemers. The most successful expression has been in Xenopus oocytes. In general, concatemers express more poorly in other systems, such as HEK293 cells, although it has been possible to study some concatemers of GABA A subunits in nonoocyte systems. 9, 29, 35 The mechanisms determining the surface expression of membrane channels in different expression systems are not fully understood. Xenopus oocytes seem to be particularly adapted for the efficient expression of many proteins, as might be expected based on the extensive burst of initial development they undergo upon fertilization. In contrast, somatic cells are differentiated, to a greater or lesser extent. Indeed, it is known that coexpression of chaperone proteins can enhance expression of particular receptors; for example, the RIC3 protein in the case of the nicotinic ␣7 receptor 36,37 or 14 -3-3 protein for the nicotinic ␣4␤2 receptor. 26, 38 In other cases, mutation of so-called "retention sequences," which tend to reduce receptor trafficking from the initial site of synthesis to the surface membrane, can enhance surface expression.
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Drawbacks to Using Concatemers
The first possible drawback to the use of concatemers is that the resulting receptors may not actually include the expected complement of subunits. This was recognized during studies of voltage-gated potassium channels. 40 One obvious example of this problem is the finding that expression of a dimer or a trimer construct of a ligand-gated ion channel subunit can, by itself, result in the expression of functional channels. 8 This is a problem, as the functional assembled receptor contains five subunits. Examination of the expressed protein, using immunoblotting, indicated that the concatemers are not degraded to separate monomeric subunits, so the question arises as to the location of excluded subunits. For nicotinic ␣4␤2 receptors, it appeared that at least some of the receptors formed when a two-subunit concatemer was expressed were actually dimers of pentamers with a bridge contributed by one of the concatemers. 8 In other cases, it has been proposed that some subunits may be in an undefined conformation that is "looped out" from the assembled receptor: 7 A functional receptor is formed by five of the subunits assembling while the extra subunit is outside the pentamer. Other examples of unexpected assemblies have been identified by using "reporter" mutations, which result in a defined change in receptor function or pharmacology. The reporter mutation is made in a specific subunit in a concatemer to determine whether that subunit is functionally present in the receptor. In some cases, it appears that a subunit may not be expressed in the assembled receptor. 7 The properties of defined receptors with these proposed abnormal subunit locations have not been extensively studied, so it is not clear how different they are from normal receptors. Instead, the focus of most research has been on defining conditions in which biochemical and functional tests indicate that the assembled receptors have the expected subunit stoichiometry.
The second possible drawback is that placing subunits in a concatemer may alter the physiologic or pharmacological properties of the resulting receptor. It has been reported that concatemers of GABA A receptors often have a shift in the concentraton dependence for activation by GABA, requiring a higher concentration. 28, 41 For nicotinic ␣4␤2 receptors, making a concatemer linked to the carboxy-terminus of the ␣4 subunit removed potentiation by 17␤-estradiol. 8, 42 This is because the action of 17␤-estradiol requires a free carboxyterminal. However, in both of these cases other properties of the receptors were normal (see Neuronal Nicotinic receptors: potentiation by 17␤-estradiol and GABA A Receptors: Potentiation by Neurosteroids). What these observations require, then, is that any investigator who uses concatemers must perform the necessary controls to demonstrate that the concatemers are structurally intact, have reasonable functional and pharmacological properties, and behave in a consistent fashion.
The generation, properties, and uses of concatemers have been reviewed elsewhere, for those interested in pursuing the topic further. [43] [44] [45] [46] Although there are some clear artifacts that can arise in the use of concatemers, overall they provide the most direct means to answer some types of questions, as we will discuss in the rest of this article.
Neuronal Nicotinic Receptors: Potentiation by 17␤-estradiol
The endogenous steroid 17␤-estradiol potentiates activation of the nicotinic ␣4␤2 receptor. Previous work has shown that the final four amino acid residues of the ␣4 subunit are required, 24, 25 and that potentiation is very sensitive to the location of these residues. For example, adding a single residue at the end abolishes potentiation, as does insertion or removal of a single residue present between the end of the fourth transmembrane region and the 17␤-estradiol domain. 24 This spatial sensitivity suggested that the domain had to be located in a precise location in the assembled receptor, and led to the hypotheses that the domain had to be on the ␣4 subunit and the ␣4 subunit that bound the steroid had to participate in binding of acetylcholine, contributing the primary side of the binding site.
We used concatemers containing two subunits, one ␣4 and one ␤2 subunit, to test these hypotheses. 42 Two concatemers were produced, one with a ␤2 subunit at the aminoterminal end (␤2-␣4), and the other with ␣4 (␣4-␤2). The concatemers were based on the work of Zhou et al., 8 and we measured voltage-clamped responses from receptors ex-pressed in Xenopus oocytes. 42 Receptors were expressed by injecting a concatemer with a free subunit. We first confirmed that the receptors formed in this way had the properties expected from studies of free subunits; for example, by expressing a concatemer with free ␣4 subunit, so the resulting receptor had properties of a receptor containing three copies of the ␣4 subunit. Furthermore, we demonstrated that we could place a mutated subunit selectively in either an acetylcholine-binding or the structural position ( fig. 2) , using the two concatemers. The data clearly demonstrated that the functional, pentameric receptors assembled when a dimer was expressed with a free subunit behaved in the fashion expected for a receptor with two copies of the concatemer and one copy of the monomer. In the case of the ␣4-␤2 concatemer, the free subunit (white color, marked with "ACh") assembles as a subunit contributing to a transmitter-binding site (shown by the gray diamonds); if the free subunit is ␤2, it contributes the complementary side, whereas if it is ␣4, it contributes the primary side. With the ␤2-␣4 concatemer, both transmitter-binding sites are inside the concatemer copies, and the free subunit assembles in the structural position ("str"). B shows the potentiation produced by 10 M 17␤-estradiol for sets of selected combinations of concatemers and free subunits. In each combination there were either zero (bar labeled "none") or only a single copy of the carboxyl-terminal binding domain (all other bars). For the middle pair of bars, the single domain was on an ␣4 subunit or on a ␤2 subunit. The mean potentiation was slightly larger when the domain was placed on a ␤2 subunit. For the upper pair of bars, potentiation was very similar when the domain was on an agonist-binding subunit or on a structural subunit. The data are the means of the average potentiation for each combination, ϩ1 SEM. The legend to the right of each bar gives the probability that the observed potentiation differs from 1 (where 1 indicates no potentiation; ns P Ͼ 0.05, * P Ͻ 0.05, *** P Ͻ 0.001), followed by the number of combinations tested (e.g., a particular concatemer expressed with a particular free subunit) and the total number of oocytes studied for all combinations. D shows the maximal potentiation ratio for 17␤-estradiol as a function of the total number of binding domains in the pentamer. Combinations of constructs were chosen that would result in one, two, three, or five intact binding domains in the pentamer (two combinations for each number), and the concentration-effect relationship for potentiation by 17␤-estradiol was determined. The fit maximum potentiation was estimated for each oocyte. The data are the mean maximal potentiation for each number of intact domains (five or six oocytes for each combination, two combinations per point) Ϯ1 SE. The curves show the best-fitting straight line (black dashed line) or geometric function (blue solid line), with Ϯ1 SE (thin dashed lines). The geometric fit is significantly better than the linear fit (P ϭ 0.02, F test). For additional information, see the full publication.
The ␣4 and ␤2 subunits have one or two proline residues at the end of the fourth transmembrane region, which allowed a reference point for the transfer of the carboxy-terminal ␤-estradiol domain.
The results show that neither of our hypotheses is correct. We found that we could move the ␤-estradiol domain to a single ␤2 subunit, eliminate it on all ␣4 subunits, and have strong potentiation by 17␤-estradiol (fig. 2B ), so our first hypothesis is disproven. We also found that the domain could be on an acetylcholine-binding subunit or the structural subunit (either a ␤2 or an ␣4 subunit) with essentially equivalent potentiation ( fig. 2B ), so our second hypothesis is disproven. We could then construct receptors with various numbers of domains included in the pentamer: zero, one, two, three, or five. The estimated maximal potentiation increased more than linearly with the numbers of domains ( fig. 2C) .
What interpretations do we make of these data? The first is that 17␤-estradiol does not have to interact with a subunit that also binds acetylcholine. This observation indicates that potentiation involves a process that affects the receptor as a whole. The second is that, although the domain is spatially very constrained, potentiation does not seem to require a particular subunit on either side of the subunit containing the domain. This suggests that the mechanism of potentiation only involves the single subunit that contains the estradiol domain. Finally, the maximal potentiation increases about 1.6-fold with each added copy of the domain. A geometric increase is consistent with a simple idea for the mechanism of potentiation. This idea is that when 17␤-estradiol binds to the C-terminal domain on a specific subunit, it results in an alteration of the structure of that subunit, which stabilizes the open-channel state of the entire receptor by adding a stabilizing energy. If 17␤-estradiol binds to another subunit in the same receptor, then there is the addition of an identical energy to stabilize the open state. Each additive energy contribution results in a multiplicative change in potentiation, because the total energy change is exponentiated to result in the change in equilibrium constant. The multiplicative increase in potentiation results from independent energetic contributions from each subunit. Because of the concerted nature of gating for the ligand-gated ion channels, these independent contributions from subunits have a global effect on receptor activation.
GABA A Receptors: Potentiation by Neurosteroids
A number of steroids potentiate activation of GABA A receptors. 15, 16 The work by Hosie et al. 20 has shown that the amino acid residue at position 241 in the ␣1 subunit (␣1 Q241) forms an essential part of the steroid-binding site. We initially explored the consequences of the fact that there are two copies of the ␣1 subunit in the assembled receptor. 41 Does a steroid need to bind to more than one subunit to potentiate the receptor, and do the two steroid-binding sites have different pharmacological properties?
We constructed two concatemers, following the work of Baumann et al. 28 One contained ␤2-␣1 subunits, and the other ␥2L-␤2-␣1 subunits (fig. 3A) . The two concatemers were expressed together, and assembled to form functional receptors. The results indicate that the presence of a single normal site conferred steroid potentiation ( fig. 3B ). When both sites were mutated, potentiation was lost. We tested the pharmacological properties of the sites by comparing the abilities of a 5␣-reduced steroid and a 5␤-reduced steroid to potentiate, and found that there was no selective effect on potentiation ( fig. 3B ). We then extended these observations by expressing receptors containing concatemers in HEK cells and examining single-channel currents elicited by GABA and modulated by steroids. 35 The single-channel properties of receptors containing concatemers of wild-type subunits were qualitatively identical to those seen with receptors formed from free subunits. The only quantitative difference was a reduction in the affinity of the resting receptor for GABA, which is also reflected in the finding that the concentration of GABA needed to produce a half-maximal whole cell response is also increased for receptors containing these concatemers. 28, 35, 41 For the wild-type concatemers, potentiation by the steroid allopregnanolone showed the same kinetic effects that we had seen in receptors composed of free subunits. We also obtained results for the receptors with the ␣1Q241L mutation in the ␥-␤-␣ concatemer; again, potentiation by allopregnanolone showed the same kinetic effects as for free subunits with intact steroid-binding sites. (Several of the concatemers expressed at such low levels that it was not possible to obtain adequate numbers of single-channel events.) Overall, the studies of single-channel currents indicate that the receptors composed of concatemers have normal functional properties and modulation by neurosteroids. The studies of whole cell responses demonstrate that the sites in the two ␣1 subunits have indistinguishable pharmacological properties, and that either can support potentiation by steroids. The results indicate that there is only a small decrease in the maximal potentiation produced by steroids when one site is removed.
We then set out to answer a second question. 47 Potentiation requires binding of both transmitter and potentiator. Is there a "privileged" relationship for particular subunits? For example, is potentiation enhanced when steroid binds to a subunit that also binds with a transmitter, or does potentiation apply equally to activation elicited by binding to either transmitter-binding site? For these studies we used a different pair of concatemers, one containing ␤2-␣1 and the other ␤2-␣1-␥2L ( fig. 3C ). We selectively ablated the GABAbinding site by the mutation ␤2Y205S 48 and the steroid site by ␣1Q241L. The mutated constructs were expressed in all possible combinations ( fig. 3D ) to examine interactions between steroid-and transmitter-binding sites, using the neurosteroid allopregnanolone to modulate GABA-elicited responses. The results did not show any significant coupling between the GABA-and steroid-binding sites on a particular subunit ( fig. 3D ). Potentiation was seen whether the GABAand steroid-binding occurred in the same ␣ subunit or not. These results indicate that neurosteroid potentiation of GABA A receptors is mediated by a generalized effect on the entire receptor.
It is interesting to note that it was possible to activate receptors in which both GABA-binding sites were ablated by using pentobarbital. 48 The data 47 indicated that either steroid site was able to potentiate responses elicited by pentobarbital, as in the case of GABA. Since the binding site for pentobarbital is presently unknown, it was not possible to examine interactions between pentobarbital and allopregnanolone. A shows an image of the receptors assembled by the concatemers used for the first set of studies. For reference, the transmitter-binding pairs are identified by a subscript; for example, the binding pair flanked by ␣ and ␥ subunits is designated "a." B shows data using two structurally distinct neurosteroids, 5␣THDOC (red bars) and 5␤THDOC (blue bars), on receptors that have specific steroid-binding sites ablated (both GABA-binding sites were intact in these constructs). The location and status of steroid-binding sites are summarized in the label on the left; for example, a(S)-b(S) means that both the ␣ a and ␣ b subunits have wild-type Q241 residues, while a(Ϫ)/b(Ϫ) indicates that ␣ a has the mutated Q241L residue. The bottom pair of bars show data for receptors with both steroid-binding sites intact; the top pair shows the loss of potentiation when both steroid-binding sites are mutated; and the middle pairs show responses when a single site is selectively removed. Note that 1 M 5␣THDOC potentiates more for all of the combinations with at least one intact site, indicating similar pharmacological properties. Potentiation of the a(S)-b(Ϫ) combination did not differ from combination with two intact steroid sites, but potentiation for the a(Ϫ)-b(S) combination was significantly less (ANOVA with Bonferroni correction). The data show mean ϩSE for potentiation by 1 M neurosteroid. The legend to the right of each bar gives the probability that the potentiation differs from 1 (ns P Ͼ 0.05, * P Ͻ 0.05, ** P Ͻ 0.01, *** P Ͻ 0.001) and the number of oocytes studied. For additional information, see the full publication. 41 C shows an image of the receptors assembled by the concatemers used for the studies of interactions between steroid-binding and transmitter-binding sites. D summarizes the results for potentiation by 1 M allopregnanolone. The legend to the left of the bars summarizes the constructs used in terms of the GABA-and steroid-binding sites. For example, the legend a(GϪ)-b(ϪS) indicates that for the "a" binding pair, the GABA site is intact (␤Y205) and the steroid site is not (␣Q241L) while for the "b" binding pair the GABA site is ablated (␤Y205S) and the steroid site is intact (␣Q241). The bottom pair is for combinations with all sites intact or with both steroid sites mutated. The middle group of three shows combinations for which the steroid site in the "a" pair is intact, while the upper group shows combinations for which the steroid site in the "b" pair is intact. For these combinations, the only difference which was significant was for the a(GϪ)-b(GϪ) comparison to a(GS)-b(GS). The legends are as in B. For additional information, see the full publication. 47 GABA ϭ ␥-aminobutyric acid; GABAA ϭ ␥-aminobutyric acid type A.
Conclusions
Steroids, either neurosteroids acting on the GABA A receptor or 17␤-estradiol acting on the nicotinic ␣4␤2 receptor, appear to act by affecting the gating properties of the receptor as a whole. Potentiation does not require that the subunit that binds a steroid also binds an agonist. For the nicotinic receptor, the steroid-binding domain is a remarkably discrete element that can be moved from one subunit to another. This may be analogous to our finding that the two copies of the ␣1 subunit in the GABA A receptor are essentially equivalent to each other. One difference between the nicotinic and the GABA A receptors is that potentiation increases steadily as we increase the number of copies of the binding domain in the nicotinic receptor, but does not change consistently when we reduce the number of intact domains in the GABA A receptor from two to one.
Steroid potentiation is mediated by interactions in or very near to the membrane-spanning regions of these receptors. It is already known that there are mutations in the second transmembrane region that enhance the stability of the open channel state. 49 -51 It is interesting that these mutations appear to act irrespective of the subunit in which they are placed, either transmitter-binding or structural, and that the energetic contributions to stabilizing the open state appear to add. It is possible that the mechanism of steroid potentiation is to directly stabilize the channel in the open channel conformation by an effect on transmembrane domain interactions, either with other channel domains or with the surrounding lipid.
The results confirm that concatemers of subunits can be used to define the number and position of subunits in assembled and functional ligand-gated ion channel family receptors. By using concatemers, we have been able to ask and answer questions about the nature of steroid-interacting sites on these receptors and how interactions between potentiating drugs and transmitters may occur.
Potentiation of GABA A receptors by steroids underlies their anesthetic actions. Neurosteroid potentiation is potent and efficacious, particularly for responses resulting from relatively low activation levels, by low concentrations of GABA or by receptors that have a low maximal activation. Potentiation reflects a global, receptor-wide effect, and the presence of multiple homologous binding sites in a single receptor provides an efficient and redundant mechanism for mediating steroid effects.
Future Directions
We are quite excited by the possibilities for future work that are opened up by the use of concatemers. In studies of anesthetic actions, there are several general areas we think are ripe for study. All of these will focus on the GABA A receptor, as the more relevant target for studies of anesthetics.
The first is the study of additional classes of anesthetics. Other anesthetics have identified binding regions in the GABA A receptor, [52] [53] [54] [55] [56] which are present on subunits that have two copies in the assembled receptor. Analogous studies to the ones we have performed with anesthetic steroids will help to clarify the properties of individual anesthetic sites and interactions with GABA-binding sites.
Another is to extend studies using voltage-clamp fluorometry. 57 By introducing the reporter fluorophore into specific locations in particular subunits, we hope to be able to examine the propagation of conformational changes induced by anesthetics.
Finally, concatemers provide the opportunity to study receptors of defined subunit stoichiometry and arrangement. Recent experiments 31, 32, 58 have demonstrated that some subunits, notably the ␦ and subunits, can assemble in different positions in the pentamer and may be able to incorporate with differing numbers of copies per receptor. Receptors containing these subunits often contribute to nonsynaptic, "tonic" GABAergic responses. We plan to extend our studies of anesthetic actions to nonsynaptic receptors, but to do so we need to have a defined population of receptors. The use of concatemers provides a path to this goal.
